Skip to main content

nexobrid

Generic: anacaulase-bcdb·Brand: Nexobrid

nexobrid: sourced relationships with 2 companies · 1 FDA decision.

nexobrid evidence translation

What we can confirm

1 FDA record

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

What is verified about nexobrid, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Removal of eschar in adult and pediatric patients with deep partial-thickness and/or full-thickness thermal burns

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
MediWound Ltd. (MDWD)
Reported 2022-12-28 · Current development: unknownSource
Approved
Vericel Corp (VCEL)
licensee · Reported 2026-02-26 · Current development: unknownSource
Removal of eschar in adult and pediatric patients with deep …
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns Burns on the face, perineum, or genitalia Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease Circumferential burns Burns in patients with significant cardiopulmonary disease, including inhalation injury NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance. Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal. NEXOBRID contains proteolytic enzymes and is indicated for eschar removal in adults and pediatric patients with deep partial thickness and/or full thickness thermal burns ( 1 ). Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns ( 1 ). Burns on the face, perineum, or genitalia ( 1 ). Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease ( 1 ). Circumferential burns ( 1 ). Burns in patients with significant cardiopulmonary disease, including inhalation injury ( 1 ). NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance ( 1 ) Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal ( 1 ).(MDWD)FDA ↗
BLA761192Type 1 - New Molecular EntityOrphan DrugStandardTopicalGel

Frequently asked questions

Which companies have sourced relationships with nexobrid?

nexobrid has dated SEC/FDA relationship records for MediWound Ltd., Vericel Corp.

What is nexobrid's latest FDA decision?

The most recent tracked FDA decision for nexobrid is Approval for 1 INDICATIONS AND USAGE NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns Burns on the face, perineum, or genitalia Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease Circumferential burns Burns in patients with significant cardiopulmonary disease, including inhalation injury NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance. Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal. NEXOBRID contains proteolytic enzymes and is indicated for eschar removal in adults and pediatric patients with deep partial thickness and/or full thickness thermal burns ( 1 ). Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns ( 1 ). Burns on the face, perineum, or genitalia ( 1 ). Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease ( 1 ). Circumferential burns ( 1 ). Burns in patients with significant cardiopulmonary disease, including inhalation injury ( 1 ). NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance ( 1 ) Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal ( 1 )., dated December 28, 2022.